BRD4 and hepatocellular carcinoma: For instance, a mechanism involving Wnt/β-catenin, Hedgehog, MAPK signaling or TGF-β pathway compensates for the effects of BRD4 inhibition on MYC expression or protein stability in leukemia, hepatocellular carcinoma, and pancreatic and colorectal cancer [39,40,41,42,43,44].